Premium
Ablation of Paroxysmal and Persistent Atrial Fibrillation: 1‐Year Follow‐Up Through Continuous Subcutaneous Monitoring
Author(s) -
POKUSHALOV EVGENY,
ROMANOV ALEXANDER,
CORBUCCI GIORGIO,
ARTYOMENKO SERGEY,
TUROV ALEX,
SHIROKOVA NATALYA,
KARASKOV ALEXANDER
Publication year - 2011
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2010.01923.x
Subject(s) - medicine , ablation , cardiology , atrial fibrillation , catheter ablation , refractory (planetary science) , paroxysmal atrial fibrillation , physics , astrobiology
Ablation of Paroxysmal and Persistent Atrial Fibrillation . Background: The aim of this prospective observational study was to identify responders to ablation through continuous subcutaneous monitoring for 1 year after ablation in patients with paroxysmal atrial fibrillation (PAF) or persistent AF (PersAF).Method:Patients with symptomatic drug refractory AF were enrolled. Real‐time three‐dimensional (3D) left atrium maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense‐Webster Inc., Diamond Bar, CA, USA). The ipsilateral left and right pulmonary veins (PVs) were encircled in 1 lesion line by circumferential PV isolation. All patients were implanted with Reveal XT (Medtronic Inc.) for continuous AF monitoring and data collected every month during the 12‐month follow‐up.Results:We enrolled 129 patients (56 ± 9 years, 102 males), all of whom were followed‐up for 12 months after the last ablation procedure: 58 (45%) had a history of PersAF. After only 1 ablation procedure, 76 (59%) of the 129 patients were AF‐free at 12‐month: 48 out of 71 (68%) in the PAF group and 28 out of 58 (48%) in the PersAF group. After 1 or more ablation procedures, 94 (73%) of the 129 patients were AF‐free 12 months after the last procedure: 57 out of 71 (80%) in the PAF group and 37 out of 58 (64%) in the PersAF group.Conclusion:Ablation is highly effective in treating AF, as assessed through detailed 1‐year continuous monitoring: success rate is higher in PAF than in PersAF patients. The use of subcutaneous monitors is a valuable means of identifying responders and nonresponders, and can potentially guide antiarrhythmic and antithrombotic therapies. (J Cardiovasc Electrophysiol, Vol. 22, pp. 369‐375)